Sunifiram / Dm-235 powder CAS:314728-85-3 CAS NO.314728-85-3

Mike(Wuhan) Biotechnology Co.,Ltd. is professional in production and export of cosmetics raw materials, plant extracts, health care raw materials and chemicals.We have GMP equipped factory and lab. We are strong in research, modern quality management system and high quality sales team.Our products are widely used in cosmetics products, health care products, nutritional supplements, beverages and pharmacy.

1. All inquiries will be replied within 12 hours.

2. Dedication to quality, supply & service.

3. Strictly on selecting raw materials.

3. OEM/ODM Available.

4. Reasonable & competitive price, fast lead time.

5. Sample is available for your evaluation & Formulation development.

6. Faster delivery:Sample order in stock and 3-7 days for bulk production.

7. We have strong cooperation with DHL, TNT, UPS, FEDEX, EMS. Or you also can choose your own shipping forwarder.

8. After-Sale Service:

1) International Authorized Third-Party Test For The Products You Demand.

2) 30 Days Warranty of quality of goods.

Sunifiram / Dm-235 powder CAS:314728-85-3 

Name: Sunifiram

other name: Dm-235

Synonyms:1-(4-Benzoyl-1-piperazinyl)-1-propanone;1-Benzoyl-4-(1-oxopropyl)-piperazine;

1-(4-Benzoylpiperazin-1-yl)propan-1-one;1-Benzoyl-4-propanoylpiperazine

CAS:314728-85-3

MF:C14H18N2O2

MW:246.30492

Sunifiram (DM-235) is a synthetic derivative of Piracetam, although due to breaking the pyrrolidone backbone it is no longer in the Racetam class of drugs (yet by being derived from them, it is still commonly associated with this class).

Packing:As required

Sunifiram has mechanisms similar to Nefiracetam in the hippocampus, and similar to that drug sunifiram shows anti-amnesiac properties and is potentially a cognitive enhancer. Its anti-amnesiac activity is several orders of magnitude greater than piracetam on a per weight basis, and preliminary evidence suggest it has a similarly low toxicity profile.

This compound is known as an AMPAkine due to exerting most of its actions via the AMPA receptor (one of the three main subsets of glutamate receptors, alongside NDMA and kainate). This enhancement of AMPA function seems to also rely on enhancing signalling via the Glycine binding site of NMDA receptors, although one minimal signalling goes through the NMDA receptor then the benefits on AMPA receptors seem dose-dependent.